The intestinal epithelium undergoes rapid renewal every 3–5 days, a process driven by intestinal stem cells (ISCs) located at ...

One-fifth of patients in a phase 1 study responded to an investigational ERK inhibitor from Merck, bolstering hopes that this type of drug could be used effectively in combination with other cancer ...

With approximately 30 to 40 percent of all marketed prescription pharmaceuticals acting on G protein-coupled receptors (GPCRs), these receptors remain attractive investigational drug targets, even ...

Phase 1 dose escalation study of the folate receptor-targeted small molecule drug conjugate EC1456. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does not include ...